NCT07122336Recruiting
Optimized Ablation of the Posterior Wall in Persistent Atrial Fibrillation
Source: ClinicalTrials.gov · Last updated 14 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The design of this study is an intervention, randomized, controlled study and contains three randomized groups：（1）PVI group；（2）PVI+PWI group;（3）PVI+PWI+EGM group.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 384 (estimated)
- First submitted
- 17 Jul 2025
- Start date
- 16 Jul 2025
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Shanghai Chest Hospital
- Diseases
- Atrial fibrillation
- NCT number
- NCT07122336
What you commit to
- Study type: Interventional
- Planned participants: 384
- From 16 Jul 2025 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- No prior attempt/pursuit of cardioversion or sinus rhythm maintenance
Other illness
- Advanced renal or hepatic failure
- Severe valvular heart disease or cyanotic congenital heart disease
Age
- Long-standing persistent AF: Continuous AF duration \>3 years
Other
- Paroxysmal AF: Episodes lasting \<7 days (or requiring pharmacologic/electrical cardioversion \<7 days)
- Contraindications to systemic anticoagulation
- Pregnancy
- Hypertrophic cardiomyopathy (HCM)
Who the study is looking for
- Age ≥18 years
- First-time ablation for persistent atrial fibrillation (PsAF)
- Persistent AF definition: Sustained episodes lasting ≥7 days but ≤3 years (including episodes requiring pharmacologic or electrical cardioversion after ≥7 days)
- Symptomatic AF with intolerance to at least one antiarrhythmic drug (AAD)
- Documented PsAF episode: At least one recorded PsAF episode within the last 2 years prior to enrollment, confirmed by: ECG,Holter monitorin, Loop recorder, Telemetry, Transtelephonic monitoring (TTM),Implantable device
- Ability and willingness to provide written informed consent
- Compliance with all study follow-up requirements
Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Chest Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.